Welcome to our dedicated page for CureVac N.V. news (Ticker: $CVAC), a resource for investors and traders seeking the latest updates and insights on CureVac N.V. stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CureVac N.V.'s stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CureVac N.V.'s position in the market.
CureVac has commenced dosing of the first participant in a Phase 2 study for its multivalent seasonal influenza vaccine candidate, developed in collaboration with GSK. This follows interim data from a Phase 2 part of a combined Phase 1/2 study, which showed the vaccine candidate elicited stronger immune responses against influenza A strains but weaker responses against influenza B strains compared to licensed vaccines. The Phase 2 study's design has been updated to match the three flu strains recommended by the WHO, excluding the B/Yamagata lineage. The study will evaluate the safety, reactogenicity, and immunogenicity of the vaccine in 500 healthy adults, split between younger (18-64) and older (65-85) participants.
CureVac (Nasdaq: CVAC) has announced its Q1 2024 financial results and business updates.
The company is in the process of an organizational redesign, reducing 150 positions by year-end to trim pandemic infrastructure and increase efficiency.
CureVac's pre-pandemic H5N1 vaccine, co-developed with GSK, received FDA Fast Track designation and is in Phase 1 development.
Settlements with Acuitas Therapeutics recognized CureVac’s patent claims, while ongoing litigation with Pfizer/BioNTech continues under seven U.S. patents, with a trial set for Q2 2025.
In Q1 2024, CureVac reported €300.2 million in cash, €12.4 million in revenue (up 74% YoY), and an operating loss of €73.3 million.